Joanne Blum, MD, PhD

Joanne Blum, MD, PhD, FACP, physician, Texas Oncology, discusses the key takeaways from the phase III ABC (anthracyclines in early breast cancer) trials, which compared docetaxel plus cyclophosphamide versus anthracycline/taxane-based chemotherapy regimens in patients with high-risk, HER2-negative breast cancer.

Joanne Blum, MD, PhD, oncologist with Texas Oncology and a member of the Breast Cancer Committee for The US Oncology Network, discuses the EMBRACA trial.